Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.54 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.48 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.48 |
| ▸ | ENTPD2 | Q9Y5L3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL437017 | 0.87 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL525149 | 0.87 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL30915796 | 0.82 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| Phosphoric Acid SCHEMBL27939255 | 0.82 | P2RY14 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL6875211 | 0.81 | P2RY2 (0.60) | P2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL18877356 | 0.81 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL29885070 | 0.80 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL8772850 | 0.79 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL19224125 | 0.78 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL14384430 | 0.77 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | WELLSTAT BIOCATALYSIS, LLC | 2005-06-09 | — | — | US | disclosed |
| US-6702705-B1 | Prodrugs activated by targeted catalytic proteins | IGEN INTERNATIONAL, INC. | 2004-03-09 | — | — | US | disclosed |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | IGEN, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6258360-B1 | BENZOATE CONJUGATES; ANTITUMOR AGENTS | IGEN INTERNATIONAL, INC. | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | SLC28A1 2502/4885SLC28A2 2810/4885SLC29A1 823/4885 |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | SLC28A1 2502/4885SLC28A2 2810/4885SLC29A1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.